MEIP MEI Pharma Inc
Price (delayed)
$2.3
Market cap
$15.32M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.73
Enterprise value
-$8.41M
MEI Pharma, Inc. is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates contains four clinical-stage assets, including zandelisib, currently in
Highlights
MEI Pharma's debt has shrunk by 100% YoY
The company's quick ratio rose by 40% YoY and by 11% QoQ
MEI Pharma's gross profit has shrunk by 100% YoY
MEIP's revenue has shrunk by 100% YoY
Key stats
What are the main financial stats of MEIP
Market
Valuations
Earnings
Shares outstanding
6.66M
Market cap
$15.32M
Enterprise value
-$8.41M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.69
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$40.61M
Net income
-$38.22M
EBIT
-$38.22M
EBITDA
-$35.74M
Free cash flow
-$36.03M
Per share
Balance sheet
Liquidity
EPS
-$5.73
EPS diluted
-$5.73
Free cash flow per share
-$5.41
Book value per share
$3.32
Revenue per share
$0
TBVPS
$3.66
Total assets
$24.39M
Total liabilities
$2.29M
Debt
$0
Equity
$22.1M
Working capital
$22.1M
Debt to equity
0
Current ratio
10.66
Quick ratio
10.38
Net debt/EBITDA
0.66
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-92.8%
Return on equity
-116.7%
Return on invested capital
-131.2%
Return on capital employed
-172.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MEIP stock price
How has the MEI Pharma stock price performed over time
Intraday
-2.95%
1 week
-5.35%
1 month
-15.44%
1 year
-43.63%
YTD
-6.5%
QTD
-6.5%
Financial performance
How have MEI Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$40.61M
Net income
-$38.22M
Gross margin
N/A
Net margin
N/A
MEI Pharma's gross profit has shrunk by 100% YoY
MEIP's revenue has shrunk by 100% YoY
MEIP's net income is up by 18% since the previous quarter
The operating income has grown by 17% from the previous quarter
Growth
What is MEI Pharma's growth rate over time
Valuation
What is MEI Pharma stock price valuation
P/E
N/A
P/B
0.69
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 18% from the previous quarter
The stock's price to book (P/B) is 75% less than its 5-year quarterly average of 2.8
The equity has shrunk by 63% YoY and by 11% QoQ
MEIP's revenue has shrunk by 100% YoY
Efficiency
How efficient is MEI Pharma business performance
MEI Pharma's ROIC has decreased by 38% from the previous quarter
MEIP's return on assets is down by 9% since the previous quarter
The ROE fell by 5% QoQ
Dividends
What is MEIP's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history
Special dividends are included in TTM DPS and yield
Financial health
How did MEI Pharma financials performed over time
The total liabilities has plunged by 88% YoY and by 20% from the previous quarter
The total assets has dropped by 69% year-on-year and by 12% since the previous quarter
MEI Pharma's debt is 100% lower than its equity
MEI Pharma's debt has shrunk by 100% YoY
MEI Pharma's debt to equity has shrunk by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.